Imigran (Sumatriptan Succinate)

Sumatriptan, the active ingredient in Imigran, works by selectively stimulating serotonin 5‑HT1B and 5‑HT1D receptors. This action causes constriction of dilated cranial blood vessels and blocks the release of inflammatory neuropeptides, thereby interrupting the pain pathway that generates migraine symptoms.

The specific dose of Imigran is determined by the prescribing healthcare professional based on the patient’s clinical condition, severity of migraine, and individual response. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for Imigran in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks before prescribing to pregnant or nursing women, and the decision should be made on a case‑by‑case basis.

To order Imigran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imigran belongs to the triptan class, which provides rapid, targeted relief of migraine by acting on serotonin receptors. Compared with non‑specific analgesics such as NSAIDs, triptans like Imigran are generally more effective for moderate to severe attacks but require careful cardiovascular assessment before use.

Imigran should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Imigran is taken orally as a tablet. The patient should swallow the tablet whole with a glass of water, preferably at the first sign of a migraine attack. It may be taken with or without food, although a full stomach can delay absorption.

The most serious risks include cardiovascular events such as coronary vasospasm, myocardial infarction, or stroke, especially in patients with pre‑existing heart disease. Additionally, serotonin syndrome can occur when combined with other serotonergic drugs, and severe allergic reactions may develop in rare cases.

Imigran is contraindicated in patients with uncontrolled cardiovascular disease, a history of myocardial infarction or stroke, severe hepatic impairment, and in those taking other vasoconstrictive agents like ergot derivatives. It should also be avoided in individuals with known hypersensitivity to sumatriptan or any tablet excipients.